Akari Therapeutics (AKTX) Operating Income (2014 - 2026)

Akari Therapeutics has disclosed Operating Income across 9 years of filings, most recently posting -$15.8 million for Q1 2026.

• Operating Income for Q1 2026 came in at -$15.8 million, down 347.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.5 million (up 76.56% YoY), and the FY2025 annual result was -$17.3 million, up 20.18% from the prior year.
• Operating Income came in at -$15.8 million for Q1 2026 at Akari Therapeutics, down from -$3.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$2.5 million in Q3 2023 to a low of -$112.0 million in Q4 2024.
• The 4-year median for Operating Income is -$4.6 million (2023), against an average of -$13.7 million.
• Across the five-year window, Operating Income sank 2100.12% in 2024 and surged 97.12% in 2025, its largest moves.
• Akari Therapeutics' Operating Income stood at -$5.1 million in 2023, then tumbled by 2100.12% to -$112.0 million in 2024, then soared by 97.12% to -$3.2 million in 2025, then slumped by 388.32% to -$15.8 million in 2026.
• The last three Operating Income figures came in at -$15.8 million (Q1 2026), -$3.2 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.